Introduction

Health Canada and the Institute for Safe Medication Practices Canada (ISMP Canada) are seeking information to better understand the current commercial compounding sector in Canada, as well as the types of commercially compounded drug products purchased by practitioners and health organizations, including clinics, long-term care homes, and hospitals.

This online questionnaire has been prepared, is being conducted, and will be analysed by ISMP Canada. Individual responses will remain anonymous.

This questionnaire is directed to practitioners and those who purchase commercially compounded drug products.

Background

Commercial Compounding

Commercial compounding is a set of activities that is distinguished from (i) traditional drug compounding, performed by pharmacies, hospitals, and healthcare practitioners for individual patients or clients, and (ii) drug manufacturing.

For the purposes of this questionnaire, the following definition is being used as a working definition for 'commercial compounding':

"reconstituting, diluting or otherwise preparing a drug or combining, admixing or mixing together two or more substances, at least one of which is a drug, to create a final product for the purposes of the sale or provision to another person, other than pursuant to or in anticipation of a prescription."

(Definition used for 'Drug Preparation Activities' in Ontario and New Brunswick; available from: http://www.ocpinfo.com/practice-education/practice-tools/collection/dpp/ and https://nbcp.in1touch.org/document/1733/2015%2007%2023%20REGS%20bilingual.pdf

The Notice regarding this questionnaire, which contains some additional background material, can be accessed here.

The questionnaire is now closed. Contact info@ismp-canada.org if you have any questions.